Media ReleasesSienna Cancer Diagnostics

View All Sienna Cancer Diagnostics News

Sienna Announces StatLab Confident in Growth Trajectory of hTERT Test in USA

Melbourne, Australia, 19 February 2018: Sienna Cancer Diagnostics Ltd, (ASX:SDX), a commercial stage, medical technology company focused on the development and commercialisation of innovative cancer-related tests, is delighted to provide shareholders with a video interview with Dan Eckert, CEO of StatLab Medical Products, Sienna’s exclusive US distributor.

Mr Eckert discusses the US market opportunity for its business, how Sienna’s hTERT product fits into StatLab’s growth strategy, the approach taken by StatLab sales personnel, including hiring the company’s first Advanced Diagnostics Sales Specialist to focus on larger opportunities and increasing industry presence at urology conferences, and the significant interest in the hTERT test shown by pathology laboratories to date.

For further information please download PDF attached:
Download this document